January 29, 2025
A Ninth Circuit panel on Wednesday affirmed the dismissal of a patent attorney's False Claims Act lawsuit alleging Allergan and Adamas Pharma fraudulently obtained patents to block generic competition for two Alzheimer's drugs, finding the information he disclosed was already publicly available and so his FCA claims are barred.
November 21, 2024
A patent attorney urged the Ninth Circuit on Thursday to revive False Claims Act allegations against Allergan over dementia drug patents, arguing his client used his expertise to discover the patents were fraudulently issued to block generics and that these are the kinds of FCA cases the government welcomes from experts.
January 30, 2024
Allergan has urged the Ninth Circuit to uphold a California federal court's decision to toss a suit from a patent litigator concerning claims of fraudulently landing dementia drug patents, arguing that the conduct has been publicly disclosed, and that the litigator did not bring any new information to the appeal.
September 01, 2023
A patent attorney wants the Ninth Circuit to undo a California federal court's decision throwing out his suit against Allergan over dementia drug patents, citing an appellate court ruling in a separate case he brought against Valeant.